04302017Headline:

Dallas-Fort Worth, Texas

HomeTexasDallas-Fort Worth

Email Shezad Malik MD JD Shezad Malik MD JD on LinkedIn Shezad Malik MD JD on Twitter Shezad Malik MD JD on Facebook Shezad Malik MD JD on Avvo
Shezad Malik MD JD
Shezad Malik MD JD
Attorney • (888) 210-9693

Jury Dings Novartis for $10.45M for Zometa Drug Jaw Injury

Comments Off

As a Texas medical doctor and Novartis Zometa personal injury and product liability attorney I am providing this Zometa litigation update.

A New York federal jury found Novartis Pharmaceuticals Corp. liable for personal injury jawbone damage to Barbara Davids who took the drug Zometa.

The verdict, is the second-largest among similar cases over Zometa. It is the fourth win for plaintiffs out of eight Zometa-related jawbone cases that have gone to trial. According to the plaintiff's attorney, the jury in the Davids case awarded $450,000 in compensatory damages and $10 million in punitive damages.

Plaintiff Lawsuit

Davids claimed that she developed side effects of osteonecrosis (ONJ), or bone death, in her jaw after taking Zometa.
During the trial, the attorneys for Davids showed the jurors a May 2003 e-mail in which a Novartis marketing employee described a proposed report linking Zometa to jawbone complications as “quite damaging.”

The largest verdict in Zometa-related jawbone osteonecrosis cases was $12.8 million, awarded to a North Carolina woman’s family in November 2010.

What is Zometa?

Zometa (zoledronic acid) is a medication used to reduce bone complications associated with multiple myeloma and bone metastases from cancers. Zometa is a bisphosphonate, which have been associated with an increased risk of ONJ. ONJ is a severe and damaging painful condition that causes decay or death of the jaw bone, often resulting in the need for surgery to remove portions of the jaw.

Federal complaints over both drugs have been consolidated together as part of a multidistrict litigation (MDL) in U.S. District Court for the District of Nashville for pretrial proceedings.

Fosamax ONJ Claims

There are Fosamax jaw necrosis lawsuits that are pending against Merck & Co. over their oral bisphosphonate medication. Fosamax is used to treat osteoporosis and reduce the risk of bone fractures, long term use of the medication has also been linked to an increased risk of jaw osteonecrosis.

The case is Davids v. Novartis, 2:06-cv-431, U.S. District Court, Eastern District of New York (Central Islip).